

ASSOBIOTECH

31 luglio 2009



N. 14 - 2009 31/07/2009
Direttore Responsabile Claudio Benedetti
Registrazione Tribunale di Milano n. 226 04/04/2006

Setup PharmaDiagen, the first Italian spin-off company addressed to fight cancer through pharmacogenetics

PharmaDiagen, the first Italian spin-off company addressed to fight cancer through pharmacogenetics, was setup in Aviano. The newborn company originated from the interest of CRO - National Cancer Institute of Aviano (Italian leader in the know-how of pharmacogenetic treatments in the oncologic field), the Italian pharmacogenetic research company Diatech and the Technologic Center of Pordenone.

PharmaDiagen will be the first Italian company embodying research, development, education, production and commercialization within the oncologic field of interest. Based on the data obtained through the monitoring of about 5000 patients in CRO, combined with Diatech's leading edge research and production, and the Technologic Center of Pordenone's know-how, PharmaDiagen will noticeably improve oncologic therapy through pharmacogenetics.

Starting from the 18th of September the new company will develop pharmacogenetic kits which will predict the response to antitumor drugs based on the patient's individual genetic profile.

For further information:

National Cancer Institute www.cro.sanita.fvg.it

Diatech www.diatech-meet.it

Technologic Center of Pordenone www.polo.pn.it